The prenatal testing & newborn screening market size has grown rapidly in recent years. It will grow from $5.52 billion in 2023 to $6.2 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth observed during the historical period can be attributed to various factors, including advancements in genetic testing, a rising maternal age, increased awareness and education regarding prenatal and newborn health, as well as changes in healthcare policies and regulations.
The prenatal testing & newborn screening market size is expected to see rapid growth in the next few years. It will grow to $9.76 billion in 2028 at a compound annual growth rate (CAGR) of 12.0%. The projected growth in the forecast period can be attributed to factors such as the increasing adoption of genetic counseling, ongoing technological advancements, the expansion of point-of-care testing, and the rise of telehealth and remote monitoring. Prominent trends in this forecast period encompass the utilization of non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), telemedicine consultations for prenatal and newborn health, maternal blood testing, as well as the focus on screening for hemoglobinopathies and sickle cell disease.
The growth of the prenatal testing and newborn screening market is significantly driven by the high prevalence of genetic diseases in infants. The World Health Organization identifies genetic diseases such as Thalassemia, Sickle Cell Anemia, Hemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, and Huntington’s disease. Among these, Sickle Cell Anemia, which predominantly affects individuals with African, American, Cuban, Central American, Saudi Arabian, and Indian ancestry, is particularly widespread. For instance, in November 2021, the National Center for Biotechnology Information reported that genetic diseases were diagnosed in 9.4% of pediatric patients, with 44.7% of these cases occurring in critically ill newborns. This heightened prevalence of genetic diseases in infants has driven the demand for prenatal testing and newborn screening.
The primary diagnostic categories within prenatal testing and newborn screening encompass non-invasive and invasive methods. Invasive diagnostic testing involves procedures that penetrate the skin or body, including techniques such as blood testing, biopsies, and colonoscopies. These diagnostic methods leverage various technologies, including screening and diagnostic technology, and are applied across a range of sectors, including hospitals and diagnostic centers.
The prenatal testing & newborn screening market research report is one of a series of new reports that provides prenatal testing & newborn screening market statistics, including prenatal testing & newborn screening industry global market size, regional shares, competitors with prenatal testing & newborn screening market share, detailed prenatal testing & newborn screening market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal testing and newborn screening tests industry. This prenatal testing and newborn screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The prenatal testing and newborn screening market is poised for growth due to an increase in birth rates. Prenatal testing assesses the health of fetuses before birth, while newborn screening detects specific medical conditions shortly after birth, enabling early intervention when necessary. For example, in May 2022, the Centers for Disease Control and Prevention reported a 1% increase in births in 2021, totaling 3,659,289 births. The general fertility rate also rose to 56.6 births per 1,000 women aged 15-44, reflecting a 1% increase from 2020. Therefore, the rising birth rate is a key driver of the prenatal testing and newborn screening market.
The growth of the prenatal testing and newborn screening market may face challenges in developing countries with relatively limited healthcare access compared to developed nations. For instance, in May 2021, the American Hospital Association warned of a looming shortage of approximately 124,000 physicians in the United States by 2033, along with a need to recruit at least 200,000 nurses annually to meet growing demand and replace retiring nurses. In many developing nations, inadequate access to healthcare services, a shortage of hospitals and healthcare professionals, and low disposable income levels are factors that hinder market growth. This limited access to healthcare services adversely impacts the expansion of the prenatal testing and newborn screening market in such regions.
The adoption of machine learning and artificial intelligence is gradually gaining traction in the prenatal testing and newborn screening market. Artificial intelligence (AI) and machine learning aid companies in the market in conducting comprehensive data analysis, providing insights about various diseases, and delivering more precise evaluations of tissue samples. For example, in September 2021, Sema4 introduced Sema4 Elements, a suite of genetic solutions that leverage artificial intelligence and information-driven digital tools for both patients and healthcare providers. These tools aim to support comprehensive healthcare management for expectant mothers and infants within the realms of reproductive and generational health.
Major companies operating in the prenatal testing and newborn screening market are actively forming strategic partnerships. These collaborations aim to bolster research, innovation, and market access, thereby enhancing the quality of healthcare services for expectant mothers and newborns. For instance, in December 2021, OZ Systems, a health technology company, partnered with PerkinElmer Inc., a provider of genetic testing, newborn and prenatal screening, to improve newborn testing through the development of cloud-based information management systems. This strategic partnership seeks to proactively identify and diagnose health conditions in newborns to prevent disabilities and save lives.
In January 2022, Exact Sciences Corp., a molecular diagnostics company, completed the acquisition of Prevention Genetics for $190 million. This acquisition enhances Exact Sciences' advanced cancer diagnostics portfolio and allows the company to enter the hereditary cancer testing (HCT) market. Prevention Genetics, a company specializing in clinical DNA (genetic) tests for prenatal testing and newborn screening, complements Exact Sciences' capabilities and expands its market presence.
Major companies operating in the prenatal testing & newborn screening market include PerkinElmer Inc., Laboratory Corporation of America Holdings (LabCorp), Natera Inc., Invitae Corporation, Centogene AG, Cradle Genomics Inc., Roche Diagnostics International AG, Quest Diagnostics Incorporated, Baebies Inc., Progenity Inc., Ravgen Inc., Strand Life Sciences Pvt. Ltd., Eurofins Scientific, Illumina Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., General Electric Company, Siemens Healthineers AG, BGI Group, QIAGEN N.V., Veracyte Inc., NIPD Genetics, Novacyt UK, Ariosa Diagnostics Inc., Verinata Health Inc., Counsyl a Myriad Company, GenPath Diagnostics, Sonic Healthcare Limited, Cepheid a Danaher Company, Guardant Health Inc., Genetron Health (Beijing) Co. Ltd.
North America was the largest region in the prenatal testing & newborn screening market in 2023. Western Europe was the second largest region in the prenatal testing and newborn screening market. The regions covered in the prenatal testing & newborn screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the prenatal testing & newborn screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada
The prenatal testing & newborn screening market includes revenues earned by entities by providing blood test services, hearing test services, CCHD screening tests, and non-invasive tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The prenatal testing & newborn screening market size is expected to see rapid growth in the next few years. It will grow to $9.76 billion in 2028 at a compound annual growth rate (CAGR) of 12.0%. The projected growth in the forecast period can be attributed to factors such as the increasing adoption of genetic counseling, ongoing technological advancements, the expansion of point-of-care testing, and the rise of telehealth and remote monitoring. Prominent trends in this forecast period encompass the utilization of non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), telemedicine consultations for prenatal and newborn health, maternal blood testing, as well as the focus on screening for hemoglobinopathies and sickle cell disease.
The growth of the prenatal testing and newborn screening market is significantly driven by the high prevalence of genetic diseases in infants. The World Health Organization identifies genetic diseases such as Thalassemia, Sickle Cell Anemia, Hemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, and Huntington’s disease. Among these, Sickle Cell Anemia, which predominantly affects individuals with African, American, Cuban, Central American, Saudi Arabian, and Indian ancestry, is particularly widespread. For instance, in November 2021, the National Center for Biotechnology Information reported that genetic diseases were diagnosed in 9.4% of pediatric patients, with 44.7% of these cases occurring in critically ill newborns. This heightened prevalence of genetic diseases in infants has driven the demand for prenatal testing and newborn screening.
The primary diagnostic categories within prenatal testing and newborn screening encompass non-invasive and invasive methods. Invasive diagnostic testing involves procedures that penetrate the skin or body, including techniques such as blood testing, biopsies, and colonoscopies. These diagnostic methods leverage various technologies, including screening and diagnostic technology, and are applied across a range of sectors, including hospitals and diagnostic centers.
The prenatal testing & newborn screening market research report is one of a series of new reports that provides prenatal testing & newborn screening market statistics, including prenatal testing & newborn screening industry global market size, regional shares, competitors with prenatal testing & newborn screening market share, detailed prenatal testing & newborn screening market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal testing and newborn screening tests industry. This prenatal testing and newborn screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The prenatal testing and newborn screening market is poised for growth due to an increase in birth rates. Prenatal testing assesses the health of fetuses before birth, while newborn screening detects specific medical conditions shortly after birth, enabling early intervention when necessary. For example, in May 2022, the Centers for Disease Control and Prevention reported a 1% increase in births in 2021, totaling 3,659,289 births. The general fertility rate also rose to 56.6 births per 1,000 women aged 15-44, reflecting a 1% increase from 2020. Therefore, the rising birth rate is a key driver of the prenatal testing and newborn screening market.
The growth of the prenatal testing and newborn screening market may face challenges in developing countries with relatively limited healthcare access compared to developed nations. For instance, in May 2021, the American Hospital Association warned of a looming shortage of approximately 124,000 physicians in the United States by 2033, along with a need to recruit at least 200,000 nurses annually to meet growing demand and replace retiring nurses. In many developing nations, inadequate access to healthcare services, a shortage of hospitals and healthcare professionals, and low disposable income levels are factors that hinder market growth. This limited access to healthcare services adversely impacts the expansion of the prenatal testing and newborn screening market in such regions.
The adoption of machine learning and artificial intelligence is gradually gaining traction in the prenatal testing and newborn screening market. Artificial intelligence (AI) and machine learning aid companies in the market in conducting comprehensive data analysis, providing insights about various diseases, and delivering more precise evaluations of tissue samples. For example, in September 2021, Sema4 introduced Sema4 Elements, a suite of genetic solutions that leverage artificial intelligence and information-driven digital tools for both patients and healthcare providers. These tools aim to support comprehensive healthcare management for expectant mothers and infants within the realms of reproductive and generational health.
Major companies operating in the prenatal testing and newborn screening market are actively forming strategic partnerships. These collaborations aim to bolster research, innovation, and market access, thereby enhancing the quality of healthcare services for expectant mothers and newborns. For instance, in December 2021, OZ Systems, a health technology company, partnered with PerkinElmer Inc., a provider of genetic testing, newborn and prenatal screening, to improve newborn testing through the development of cloud-based information management systems. This strategic partnership seeks to proactively identify and diagnose health conditions in newborns to prevent disabilities and save lives.
In January 2022, Exact Sciences Corp., a molecular diagnostics company, completed the acquisition of Prevention Genetics for $190 million. This acquisition enhances Exact Sciences' advanced cancer diagnostics portfolio and allows the company to enter the hereditary cancer testing (HCT) market. Prevention Genetics, a company specializing in clinical DNA (genetic) tests for prenatal testing and newborn screening, complements Exact Sciences' capabilities and expands its market presence.
Major companies operating in the prenatal testing & newborn screening market include PerkinElmer Inc., Laboratory Corporation of America Holdings (LabCorp), Natera Inc., Invitae Corporation, Centogene AG, Cradle Genomics Inc., Roche Diagnostics International AG, Quest Diagnostics Incorporated, Baebies Inc., Progenity Inc., Ravgen Inc., Strand Life Sciences Pvt. Ltd., Eurofins Scientific, Illumina Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., General Electric Company, Siemens Healthineers AG, BGI Group, QIAGEN N.V., Veracyte Inc., NIPD Genetics, Novacyt UK, Ariosa Diagnostics Inc., Verinata Health Inc., Counsyl a Myriad Company, GenPath Diagnostics, Sonic Healthcare Limited, Cepheid a Danaher Company, Guardant Health Inc., Genetron Health (Beijing) Co. Ltd.
North America was the largest region in the prenatal testing & newborn screening market in 2023. Western Europe was the second largest region in the prenatal testing and newborn screening market. The regions covered in the prenatal testing & newborn screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the prenatal testing & newborn screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada
The prenatal testing & newborn screening market includes revenues earned by entities by providing blood test services, hearing test services, CCHD screening tests, and non-invasive tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Prenatal Testing and Newborn Screening Market Characteristics3. Prenatal Testing and Newborn Screening Market Trends And Strategies31. Global Prenatal Testing and Newborn Screening Market Competitive Benchmarking32. Global Prenatal Testing and Newborn Screening Market Competitive Dashboard33. Key Mergers And Acquisitions In The Prenatal Testing and Newborn Screening Market
4. Prenatal Testing and Newborn Screening Market - Macro Economic Scenario
5. Global Prenatal Testing and Newborn Screening Market Size and Growth
6. Prenatal Testing and Newborn Screening Market Segmentation
7. Prenatal Testing and Newborn Screening Market Regional And Country Analysis
8. Asia-Pacific Prenatal Testing and Newborn Screening Market
9. China Prenatal Testing and Newborn Screening Market
10. India Prenatal Testing and Newborn Screening Market
11. Japan Prenatal Testing and Newborn Screening Market
12. Australia Prenatal Testing and Newborn Screening Market
13. Indonesia Prenatal Testing and Newborn Screening Market
14. South Korea Prenatal Testing and Newborn Screening Market
15. Western Europe Prenatal Testing and Newborn Screening Market
16. UK Prenatal Testing and Newborn Screening Market
17. Germany Prenatal Testing and Newborn Screening Market
18. France Prenatal Testing and Newborn Screening Market
19. Italy Prenatal Testing and Newborn Screening Market
20. Spain Prenatal Testing and Newborn Screening Market
21. Eastern Europe Prenatal Testing and Newborn Screening Market
22. Russia Prenatal Testing and Newborn Screening Market
23. North America Prenatal Testing and Newborn Screening Market
24. USA Prenatal Testing and Newborn Screening Market
25. Canada Prenatal Testing and Newborn Screening Market
26. South America Prenatal Testing and Newborn Screening Market
27. Brazil Prenatal Testing and Newborn Screening Market
28. Middle East Prenatal Testing and Newborn Screening Market
29. Africa Prenatal Testing and Newborn Screening Market
30. Prenatal Testing and Newborn Screening Market Competitive Landscape And Company Profiles
34. Prenatal Testing and Newborn Screening Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
Prenatal Testing & Newborn Screening Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on prenatal testing & newborn screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for prenatal testing & newborn screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
- Markets Covered: 1) By Diagnostic Type: Non-Invasive; Invasive; 2) By Technology: Screening Technology; Diagnostic Technology; 3) By End user: Hospitals; Diagnostic centers
- Companies Mentioned: PerkinElmer Inc.; Laboratory Corporation of America Holdings (LabCorp); Natera Inc.; Invitae Corporation; Centogene AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- PerkinElmer Inc.
- Laboratory Corporation of America Holdings (LabCorp)
- Natera Inc.
- Invitae Corporation
- Centogene AG
- Cradle Genomics Inc.
- Roche Diagnostics International AG
- Quest Diagnostics Incorporated
- Baebies Inc.
- Progenity Inc.
- Ravgen Inc.
- Strand Life Sciences Pvt. Ltd.
- Eurofins Scientific
- Illumina Inc.
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories Inc.
- General Electric Company
- Siemens Healthineers AG
- BGI Group
- QIAGEN N.V.
- Veracyte Inc.
- NIPD Genetics
- Novacyt UK
- Ariosa Diagnostics Inc.
- Verinata Health Inc.
- Counsyl a Myriad Company
- GenPath Diagnostics
- Sonic Healthcare Limited
- Cepheid a Danaher Company
- Guardant Health Inc.
- Genetron Health (Beijing) Co. Ltd.
Methodology
LOADING...
